Bolar clonidine patch
Executive Summary
Firms anticipates product approval filing within six months. Exclusivity for Boehringer Ingelheim's Catapres TTS is scheduled to expire in October. Bolar already markets a transdermal nitroglycerin patch, developed by Hercon.